Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.

about

Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.

Item

http://www.wikidata.org/entity/Q38667138

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Copper (II) complexes of biden ...... f platinum sensitivity status.

@en

type

Item

label

Copper (II) complexes of biden ...... f platinum sensitivity status.

@en

prefLabel

Copper (II) complexes of biden ...... f platinum sensitivity status.

@en

P1476

Copper (II) complexes of biden ...... f platinum sensitivity status.

@en

P2093

Cody Lo

http://www.w3.org/2001/XMLSchema#string

Gemma M Ryan

http://www.w3.org/2001/XMLSchema#string

Wieslawa H Dragowska

http://www.w3.org/2001/XMLSchema#string

P2860

Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.

Cisplatin ototoxicity and protection: clinical and experimental studies

Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline)

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development

Cellular processing of platinum anticancer drugs

Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells.

A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.

Platinum compounds: a new class of potent antitumour agents.

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

P2888

s10637-017-0488-2

P304

682-690

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-017-0488-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marcel B Bally

Mohamed Wehbe

Ada W Y Leung

P577

2017-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090832477

http://www.w3.org/2001/XMLSchema#string

P698

28733701

http://www.w3.org/2001/XMLSchema#string

P932

5694505

http://www.w3.org/2001/XMLSchema#string